Clinical Trials That Do Not Use
the iPS Cell Stock

In Japan, three clinical trials were conducted without using the iPS cell stock for regenerative medicine.

Since we started providing the iPS cell stock for regenerative medicine in 2015, many studies have used them. However, some diseases and treatment methods cannot be handled using the iPS cell stock but require individualized iPS cells.

Start year	Target disease	Origin of iPS cells	Reference
2014	Start year: 2014	Age-related macular degeneration	Target disease: Age-related macular degeneration Origin of iPS cells: Patient's own cells	Patient's own cells	CiRA News March 16, 2017 The New England Journal of Medicine, March 16, 2017
2019	Start year: 2019	Thrombocytopenia	Target disease: Thrombocytopenia Origin of iPS cells: Patient's own cells	Patient's own cells	Blood, Sep 16, 2022
2020	Start year: 2020	Head and Neck Cancer	Target disease: Head and Neck Cancer Origin of iPS cells: Healthy Adult Cells	Healthy Adult Cells	Inflammation and Regeneration, May 12, 2023

Clinical studies conducted without the iPS cell stock for regenerative medicine.